JP2021075563A5 - - Google Patents

Download PDF

Info

Publication number
JP2021075563A5
JP2021075563A5 JP2021020446A JP2021020446A JP2021075563A5 JP 2021075563 A5 JP2021075563 A5 JP 2021075563A5 JP 2021020446 A JP2021020446 A JP 2021020446A JP 2021020446 A JP2021020446 A JP 2021020446A JP 2021075563 A5 JP2021075563 A5 JP 2021075563A5
Authority
JP
Japan
Prior art keywords
composition
oxo
composition according
fibrosis
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021020446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021075563A (ja
JP7229285B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021075563A publication Critical patent/JP2021075563A/ja
Publication of JP2021075563A5 publication Critical patent/JP2021075563A5/ja
Priority to JP2023020423A priority Critical patent/JP2023065454A/ja
Application granted granted Critical
Publication of JP7229285B2 publication Critical patent/JP7229285B2/ja
Priority to JP2025002652A priority patent/JP2025061087A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021020446A 2015-05-13 2021-02-12 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法 Active JP7229285B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023020423A JP2023065454A (ja) 2015-05-13 2023-02-14 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法
JP2025002652A JP2025061087A (ja) 2015-05-13 2025-01-08 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160863P 2015-05-13 2015-05-13
US62/160,863 2015-05-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017559093A Division JP2018524274A (ja) 2015-05-13 2016-05-12 15−オキソ−epaまたは15−オキソ−dglaを含む組成物、ならびにその作製及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020423A Division JP2023065454A (ja) 2015-05-13 2023-02-14 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法

Publications (3)

Publication Number Publication Date
JP2021075563A JP2021075563A (ja) 2021-05-20
JP2021075563A5 true JP2021075563A5 (enExample) 2022-01-11
JP7229285B2 JP7229285B2 (ja) 2023-02-27

Family

ID=56131573

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017559093A Pending JP2018524274A (ja) 2015-05-13 2016-05-12 15−オキソ−epaまたは15−オキソ−dglaを含む組成物、ならびにその作製及び使用方法
JP2021020446A Active JP7229285B2 (ja) 2015-05-13 2021-02-12 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法
JP2023020423A Withdrawn JP2023065454A (ja) 2015-05-13 2023-02-14 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法
JP2025002652A Pending JP2025061087A (ja) 2015-05-13 2025-01-08 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017559093A Pending JP2018524274A (ja) 2015-05-13 2016-05-12 15−オキソ−epaまたは15−オキソ−dglaを含む組成物、ならびにその作製及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023020423A Withdrawn JP2023065454A (ja) 2015-05-13 2023-02-14 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法
JP2025002652A Pending JP2025061087A (ja) 2015-05-13 2025-01-08 15-オキソ-epaまたは15-オキソ-dglaを含む組成物、ならびにその作製及び使用方法

Country Status (7)

Country Link
US (4) US10047033B2 (enExample)
EP (1) EP3294282A1 (enExample)
JP (4) JP2018524274A (enExample)
CN (3) CN117402059A (enExample)
HK (1) HK1250345A1 (enExample)
MA (1) MA47141A (enExample)
WO (1) WO2016181221A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151825B1 (en) 2014-06-04 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
HK1250345A1 (zh) * 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
WO2020079250A1 (en) * 2018-10-18 2020-04-23 Ds Biopharma Limited Dgla and/or 15-hetre for treating inflammatory, fibrotic, and proliferative conditions
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
DE68924714T2 (de) 1988-01-14 1996-05-02 Anders Frithz Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
CA1334002C (en) 1988-09-28 1995-01-17 Barry D. Sears Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
DE4238869C2 (de) 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
BR9405620A (pt) 1993-10-01 1999-09-08 Scherer Corp R P Cápsula de gelatina contendo fragr‰ncia, e, processo para sua preparação
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
ATE344226T1 (de) 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
JP2002047176A (ja) 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd IgE産生抑制剤
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
ES2238568T3 (es) 2001-05-30 2005-09-01 Laxdale Limited Uso del coenzima q (ubiquinona) y acido eicosapentaenoico (epa) para el tratamiento del linfoma no hodgkin y trastornos psiquiatricos o neurologicos.
JP2003155233A (ja) 2001-11-16 2003-05-27 Idemitsu Technofine Co Ltd 塗布剤
JPWO2004048497A1 (ja) 2002-11-22 2006-03-30 日本水産株式会社 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US9006287B2 (en) 2005-02-14 2015-04-14 Suntory Holdings Limited Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防/改善・治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8658787B2 (en) 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP6399655B2 (ja) 2012-01-06 2018-10-03 オムセラ・ファーマシューティカルズ・インコーポレイテッド 遊離酸型のオメガ−3多価不飽和脂肪酸のdpa濃縮組成物
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2833740T3 (da) 2012-04-04 2017-01-02 Pronova Biopharma Norge As Sammensætninger omfattende omega-3-fedtsyrer og D-vitamin til acne vulgaris og/eller eksem og fremgangsmåder og anvendelser deraf
PT2934505T (pt) * 2012-12-24 2021-07-02 Qualitas Health Inc Formulação de ácido eicosapentaenoico (epa)
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
SG11201507288UA (en) * 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
EP3151825B1 (en) 2014-06-04 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
HK1250345A1 (zh) 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
BR122023026625A2 (pt) 2015-12-18 2024-01-16 Afimmune Limited Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
WO2017118911A1 (en) 2016-01-07 2017-07-13 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Similar Documents

Publication Publication Date Title
JP2021075563A5 (enExample)
JP2023065454A5 (enExample)
JP2021063088A5 (enExample)
JP2015508068A5 (enExample)
US6426367B1 (en) Methods for selectively occluding blood supplies to neoplasias
US10363235B2 (en) Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same
DE60301878T2 (de) Pharmazeutische zusammensetzung enthaltend ein alpha-ketoalkansäureester oder -amid und milchsäure oder ein milchsäuresalz
Vineberg Restoration of coronary circulation by anastomosis
Lowry et al. Primary osteosarcoma of the heart
RU2013126522A (ru) Лизурид, тергурид и их производные для применения в профилактике и/или лечении фиброзных изменений
KR100874626B1 (ko) 담즙 분비 촉진 조성물
JPWO2020139525A5 (enExample)
Jugdutt et al. Hepatic artery ligation in treatment of carcinoid syndrome
JPWO2019234240A5 (enExample)
Holden et al. Late results of bronchography using Dionosil oily
JP7535373B2 (ja) 肝硬変の治療のための組成物
JPH0120A (ja) 臓器保護剤
ZEPPA et al. Medial degeneration and aneurysm of the hepatic artery
JP2007504097A5 (enExample)
CN120227441B (zh) 用于动脉粥样硬化联合治疗的药物组合物
Dreizen et al. The effect of experimentally induced generalized medial arteriosclerosis on the oral vessels of the rat
JP2003504404A (ja) 抗虚血薬
WO2022182703A1 (en) Compositions and methods for treating inflammatory bowel disease
JPS63211231A (ja) 雄性不妊動物の治療剤
JPH05294834A (ja) 活性型ビタミンd含有治療剤